Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 10:00 save search
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.545 3.81% 1.67% 190K
|
Health Technology
|
| O: -20.14%
H: 0.0%
C: 0.0%
als biomarker publication cell trial therapeutics
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.545 3.81% 1.67% 190K
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published: 2024-03-21 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9469 2.57% -4.33% 25K
|
n/a
|
| O: 2.75%
H: 3.74%
C: -6.54%
bnc210 trial results
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Published: 2024-01-24 (Crawled : 10:00) - biospace.com/
ABVX | $15.89 0.19% 0.63% 7.2K
|
n/a
|
| O: -1.76%
H: 3.24%
C: 1.36%
active review trial
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-12-12 (Crawled : 10:00) - globenewswire.com
ADCT | $4.78 -3.82% 1.88% 280K
|
Health Technology
|
| O: 1.0%
H: 2.97%
C: 1.98%
zynlonta trial therapeutics results
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
Published: 2023-10-11 (Crawled : 10:00) - globenewswire.com
BCDA P | $0.3795 0.93% -2.56% 73K
|
Health Technology
|
| O: 4.46%
H: 27.73%
C: 22.82%
cardiamp trial
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $16.22 4.65% 4.56% 440K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9469 2.57% -4.33% 25K
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Published: 2023-09-25 (Crawled : 10:00) - revivapharma.com
RVPH | $3.02 -1.31% -1.32% 73K
|
|
| O: 0.0%
H: 2.1%
C: -1.84%
brilaroxazine schizophrenia trial
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Published: 2023-09-11 (Crawled : 10:00) - globenewswire.com
CING | $0.87 -0.99% -2.9% 24K
|
|
| O: -6.51%
H: 6.19%
C: 6.19%
adhd trial results
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
Published: 2023-08-16 (Crawled : 10:00) - prnewswire.com
IDYA | News | $39.85 2.13% 2.08% 1.4M
|
Health Technology
|
| O: 0.43%
H: 2.99%
C: -1.79%
melanoma trial phase 2
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Published: 2023-08-08 (Crawled : 10:00) - globenewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 15.34%
H: 3.26%
C: 1.64%
obesity risk trial cardiovascular
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-07-27 (Crawled : 10:00) - biospace.com/
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.86%
enhertu her2 tumors trial
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
Published: 2023-07-24 (Crawled : 10:00) - globenewswire.com
BLTE | $37.27 0.73% 0.62% 33K
|
n/a
|
| O: 0.17%
H: 7.09%
C: 4.0%
disease global trial
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
Published: 2023-07-03 (Crawled : 10:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
zp8396 pharma positive trial results
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
Published: 2023-06-29 (Crawled : 10:00) - globenewswire.com
MNOV | $1.355 1.88% -3.73% 8K
|
Health Technology
|
| O: 0.89%
H: 1.76%
C: 0.88%
mn-166 alcohol presentation research meeting trial results
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Published: 2023-06-29 (Crawled : 10:00) - globenewswire.com
BTAI | News | $2.71 -8.75% -10.0% 870K
|
Health Technology
|
| O: -51.1%
H: 9.49%
C: -26.04%
bxcl501 alzheimer’s positive treatment topline trial therapeutics results
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association
Published: 2023-06-09 (Crawled : 10:00) - globenewswire.com
KROS | $56.24 1.9% 1.68% 310K
|
Health Technology
|
| O: -2.78%
H: 0.04%
C: -7.79%
ker-050 association preclinical program trial therapeutics results study
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Published: 2023-06-07 (Crawled : 10:00) - prnewswire.com
DRRX | $0.8835 4.76% 7.02% 140K
|
Health Technology
|
| O: 0.54%
H: 2.7%
C: -2.34%
hepatitis trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.